View Archive

Credit Designation

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 2.0 Contact Hours.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Pfizer Inc.

Virtual Tumor Board®: The Importance of Molecular Testing in Lung Cancer to Optimize Precision Care

Virtual Tumor Board®: The Importance of Molecular Testing in Lung Cancer to Optimize Precision Care

Tuesday, October 13, 2020

Live, Interactive Virtual Webcast!

6:00 PM – 8:00 PM EST


The rapid development of targeted therapies, whether available in the clinic or in clinical trials, has put increased emphasis and urgency on the critical need for implementing genomic testing into diagnostic and treatment strategies for patients with non–small cell lung cancer (NSCLC). Identifying mutations in oncogenic drivers such as EGFR, ALK, ROS1, and BRAF, as well as other targets such as RET, NTRK, and MET exon 14 mutations may play a key role in treatment decision making. In addition, there is ongoing research into therapies for patients with EGFR exon 20 mutations, KRAS mutations, and HER2 mutations. Rapid and reliable large-scale testing using next-generation sequencing and perhaps liquid biopsy is essential in the appropriate management of this disease.

This Virtual Tumor Board®: The Importance of Molecular Testing in Lung Cancer in the Era of Immunotherapy is designed to aid physicians in assessing the wealth of emerging data in treating NSCLC, choosing appropriate treatment based upon patient and tumor characteristics, and applying novel management strategies to their practices to improve the care of patients. This program focuses on testing strategies and application of evolving clinical trial data for more common mutational drivers in a practical, “real world” tumor board format that physicians are accustomed to in their clinical practices.

Benefits of Attending

  • Ask questions about your patients and receive guidance from the experts on interpretation of core concepts related to molecular testing in lung cancer
  • Hear expert faculty share their own real-world experiences, approaches, preferences, and perspectives on treating patients with NSCLC
  • Learn about the potential clinical impact of novel targeted agents based on recent data sets from the latest NSCLC clinical trials
  • Integrate recent data on targeted treatments into clinical practice and apply to the care of your patients with NSCLC

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Pfizer Inc.

Target Audience

This educational activity is directed toward medical oncologists, pathologists, and fellows involved in the treatment and management of patients with NSCLC. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of NSCLC may also participate.

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Describe the role of tissue- and liquid-based genomic testing for the identification of actionable molecular alterations in NSCLC
  • Evaluate best practices in tissue stewardship and conservation to facilitate comprehensive molecular testing in NSCLC
  • Assess efficacy and safety data for novel targeted therapies based on predictive molecular biomarkers
  • Incorporate emerging evidence regarding diagnostic testing and targeted therapies into challenging clinical scenarios in NSCLC

Program Chair

Suresh S. Ramalingam, MD, FACP, FASCO
Suresh S. Ramalingam, MD, FACP, FASCO
Roberto C. Goizueta Distinguished Chair for Cancer Research
Deputy Director, Winship Cancer Institute of Emory University
Emory University School of Medicine
Atlanta, GA


2 Ways to Register
  1. Online: click here.
  2. Phone: Please call (888) 949-0045 or (609) 378-3701.
Physicians' Education Resource®
2 Clarke Drive
Suite 110
Cranbury, NJ 08512
Registration Fee - Free

For registration assistance, please email info@gotoper.com, or call (888) 949-0045 or (609) 378-3701.

Physicians' Education Resource®, LLC reserves the exclusive rights to all recordings or reproductions of the conference and supporting materials. Unauthorized recording, by any means, is expressly prohibited.  This includes, but is not limited to, recording of presentations or reproductions of supporting audio/visual materials, exhibits, and other supporting Continuing Education materials.

Meeting information is accurate at the time of posting.


You must be logged in to PER to register for this meeting

Or Register for PER now

*Required Fields

Login Information

Registration Information

Professional Information


Calendar of Events
Filter By